Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
July 16, 2024 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
July 11, 2024 09:20 ET
|
GRI Bio, Inc.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
July 11, 2024 08:00 ET
|
Palisade Bio, Inc.
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has...
Greenwich LifeSciences Set to Join Russell 2000 Index Again
June 26, 2024 07:33 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Aridis Provides Corporate Update
June 24, 2024 17:58 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
June 24, 2024 09:00 ET
|
Palisade Bio, Inc.
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
June 24, 2024 08:30 ET
|
Biofrontera Inc.
The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity...
Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark
June 21, 2024 14:37 ET
|
Nordicus Partners Corporation
Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
June 21, 2024 08:15 ET
|
Palisade Bio, Inc.
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC...
Greenwich LifeSciences Announces $2.5 Million Private Placement
June 14, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III...